Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 2;13(1):3064.
doi: 10.1038/s41467-022-30721-w.

A supramolecular photosensitizer derived from an Arene-Ru(II) complex self-assembly for NIR activated photodynamic and photothermal therapy

Affiliations

A supramolecular photosensitizer derived from an Arene-Ru(II) complex self-assembly for NIR activated photodynamic and photothermal therapy

Gang Xu et al. Nat Commun. .

Abstract

Effective photosensitizers are of particular importance for the widespread clinical utilization of phototherapy. However, conventional photosensitizers are usually plagued by short-wavelength absorption, inadequate photostability, low reactive oxygen species (ROS) quantum yields, and aggregation-caused ROS quenching. Here, we report a near-infrared (NIR)-supramolecular photosensitizer (RuDA) via self-assembly of an organometallic Ru(II)-arene complex in aqueous solution. RuDA can generate singlet oxygen (1O2) only in aggregate state, showing distinct aggregation-induced 1O2 generation behavior due to the greatly increased singlet-triplet intersystem crossing process. Upon 808 nm laser irradiation, RuDA with excellent photostability displays efficient 1O2 and heat generation in a 1O2 quantum yield of 16.4% (FDA-approved indocyanine green: ΦΔ = 0.2%) together with high photothermal conversion efficiency of 24.2% (commercial gold nanorods: 21.0%, gold nanoshells: 13.0%). In addition, RuDA-NPs with good biocompatibility can be preferably accumulated at tumor sites, inducing significant tumor regression with a 95.2% tumor volume reduction in vivo during photodynamic therapy. This aggregation enhanced photodynamic therapy provides a strategy for the design of photosensitizers with promising photophysical and photochemical characteristics.

PubMed Disclaimer

Conflict of interest statement

Southeast University has applied for a Chinese patent (Patent Number: CN 111808144 A) of RuDA reported here with J.Z. listed as one of the inventors. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Schematic illustration of RuDA-NPs for phototherapy.
A Schematic illustration of the photophysical mechanism of RuDA in monomer and aggregate forms for cancer phototherapy, B synthesis of RuDA-NPs, and C RuDA-NPs for NIR-activated PDT and PTT.
Fig. 2
Fig. 2. Photo-physicochemical properties of RuDA.
A Chemical structure of RuDA. B Absorption spectra of RuDA in mixtures of DMF and water at various ratios. C Time-dependent variation in the normalized absorbance values of RuDA (800 nm) and ICG (779 nm) under 808 nm laser irradiation at 0.5 W cm−2. D Photodegradation of ABDA indicative of 1O2 generation induced by RuDA in DMF/H2O mixtures with different water fractions under 808 nm laser irradiation at 0.5 W cm−2.
Fig. 3
Fig. 3. Quantum-chemical calculations of RuDA.
A Calculated HOMOs and LUMOs of RuDA in monomeric and dimeric forms. B Singlet and triplet energy levels of of RuDA in monomer and dimer, respectively. C Calculated energy levels and possible ISC channels of RuDA in monomeric C and dimeric D forms. The arrows refer to the possible ISC channels.
Fig. 4
Fig. 4. Photoelectrochemical properties of RuDA and RuET.
A Chemical structure of RuET. B Absorption spectra of RuET in mixtures of DMF and water at various ratios. C EIS Nyquist plots of RuDA and RuET. D Photocurrent responses of RuDA and RuET under 808 nm laser irradiation.
Fig. 5
Fig. 5. The characterization and photothermal properties of RuDA-NPs.
A DLS analysis and TEM image (inset) of RuDA-NPs. B Thermal images of RuDA-NPs at different concentrations under 808 nm (0.5 W cm-2) laser irradiation. C Photothermal conversion profile of RuDA-NPs at different concentrations, which is the quantitative data of B. D Temperature elevation of RuDA-NPs and ICG during five cycles of heating-cooling processes.
Fig. 6
Fig. 6. In vitro phototherapy efficiencies of RuDA and RuDA-NPs.
A RuDA- and B RuDA-NPs-dose dependent cell viabilities in MDA-MB-231 cells in the presence or absence of Vc (0.5 mM), respectively. Error bars, mean ± SD (n = 3). Unpaired, two-sided t tests *p < 0.05, **p < 0.01, and ***p < 0.001. C Live/dead cell staining assays using calcein AM and propidium iodide as fluorescence probes. Scale bars: 30μm. A representative image of three biological replicates from each group is shown. D Confocal fluorescence images of ROS generation in MDA-MB-231 cells under different treatment conditions. Green fluorescence from DCF indicates the presence of ROS. Irradiation was performed using 808 nm laser at 0.5 W cm−2 for 10 min (300 J cm−2). Scale bars: 30 μm. A representative image of three biological replicates from each group is shown. E Flow cytometry analysis for apoptosis of MDA-MB-231 cells treated with RuDA-NPs (50 μM) or RuDA (50 μM) in the presence and absence of Vc (0.5 mM), and irradiated with or without 808 nm laser (0.5 W cm−2) for 10 min. A representative image of three biological replicates from each group is shown. F Cellular Nrf-2, HSP70, and HO-1 expressions of MDA-MB-231 cells treated with RuDA-NPs (50 μM) with or without 808 nm laser irradiation (0.5 W cm−2, 10 min, 300 J cm−2). A representative image of two biological replicates from each group is shown.
Fig. 7
Fig. 7. Ex vivo biodistribution and in vivo PA imaging.
A Ex vivo tissue distribution of RuDA-NPs in mice determined by the content of Ru (% injected dose (ID) of Ru per gram of tissues) at different post injection time. The data represent the mean ± SD (n = 3). Unpaired, two-sided t tests *p < 0.05, **p < 0.01, and ***p < 0.001. B In vivo PA images of tumor sites under excitation at 808 nm after intravenous injection of RuDA-NPs (10 μmol kg−1) at different time points. C Ru excreted out of the mice body via urine and feces after intravenous administration of RuDA-NPs (10 μmol kg−1) at different time intervals. The data represent the mean ± SD (n = 3).
Fig. 8
Fig. 8. In vivo phototherapy efficacies of RuDA and RuDA-NPs on tumors.
A IR thermal images of MDA-MB-231 tumor-bearing mice irradiated with 808 nm laser for different time at 8 h post injection. A representative image of four biological replicates from each group is shown. B Relative tumor volume and C average tumor weights for different groups of mice during the therapeutic process. D Body weight curves of different groups of mice. Irradiation was performed with 808 nm laser at 0.5 W cm−2 for 10 min (300 J cm−2). Error bars, mean ± SD (n = 3). Unpaired, two-sided t tests *p < 0.05, **p < 0.01, and ***p < 0.001. E H&E staining images of major organs and tumors from different treatment groups, including Saline, Saline + Laser, RuDA, RuDA + Laser, RuDA-NPs, and RuDA-NPs + Laser groups. Scale bars: 60 μm.

References

    1. Li J, Pu K. Development of organic semiconducting materials for deep-tissue optical imaging, phototherapy and photoactivation. Chem. Soc. Rev. 2019;48:38–71. doi: 10.1039/C8CS00001H. - DOI - PubMed
    1. Zhao X, Liu J, Fan J, Chao H, Peng X. Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: from molecular design to application. Chem. Soc. Rev. 2021;50:4185–4219. doi: 10.1039/D0CS00173B. - DOI - PubMed
    1. Dai J, et al. Efficient near-infrared photosensitizer with aggregation-induced emission for imaging-guided photodynamic therapy in multiple xenograft tumor models. ACS Nano. 2020;14:854–866. doi: 10.1021/acsnano.9b07972. - DOI - PubMed
    1. Yang B, Chen Y, Shi J. Reactive oxygen species (ROS)-based nanomedicine. Chem. Rev. 2019;119:4881–4985. doi: 10.1021/acs.chemrev.8b00626. - DOI - PubMed
    1. Guo Z, et al. Bifunctional platinated nanoparticles for photoinduced tumor ablation. Adv. Mater. 2016;28:10155–10164. doi: 10.1002/adma.201602738. - DOI - PubMed

Publication types